Atossa Therapeutics, Inc. (ATOS) 10-Year Financial Performance & Capital Metrics

ATOS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Show more

Revenue $0
EBITDA -$28M +12.0%
Net Income -$26M +15.3%
EPS (Diluted) -0.20 +16.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -31.39% -9.0%
ROIC -1404.93% -187.5%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-12.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM-10.68%

ROCE

10Y Avg-106.27%

5Y Avg-36.58%

3Y Avg-28.55%

Latest-34%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.76K	0	0	0	0	0	0	0	0	0
Revenue Growth %	-1%	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	132.41K	303.48K	128.99K	44.2K	0	0	0	0	0	0
COGS % of Revenue	75.32%	-	-	-	-	-	-	-	-	-
Gross Profit+	-130.65K	-303.48K	-128.99K	-44.2K	0	0	0	0	0	0
Gross Margin %	-74.32%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-1.71%	-1.32%	0.57%	0.66%	1%	-	-	-	-	-
Operating Expenses+	12.63M	7.25M	7.19M	11.43M	17.27M	14.61M	20.52M	27.69M	31.38M	27.62M
OpEx % of Revenue	7183.14%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	10.27M	6.48M	4.86M	7.22M	10.62M	8M	11.31M	12.61M	14.04M	13.5M
SG&A % of Revenue	5840.94%	-	-	-	-	-	-	-	-	-
Research & Development	2.36M	770.43K	2.33M	4.21M	7.13M	6.61M	9.21M	15.08M	17.33M	14.12M
R&D % of Revenue	1342.2%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	718.97K	154	29.3K	-486.55K	0	0	0	0	0
Operating Income+	-12.76M	-7.97M	-7.65M	-11.43M	-17.27M	-14.61M	-20.52M	-27.69M	-31.38M	-27.62M
Operating Margin %	-7257.46%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.13%	0.38%	0.04%	-0.49%	-0.51%	0.15%	-0.4%	-0.35%	-0.13%	0.12%
EBITDA+	-12.49M	-7.67M	-7.52M	-11.39M	-17.21M	-14.56M	-20.5M	-27.68M	-31.35M	-27.6M
EBITDA Margin %	-7102.38%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.11%	0.39%	0.02%	-0.51%	-0.51%	0.15%	-0.41%	-0.35%	-0.13%	0.12%
D&A (Non-Cash Add-back)	272.63K	303.48K	128.99K	44.2K	52.79K	47K	23K	8K	23K	17K
EBIT	-12.76M	-6.37M	-7.93M	-11.43M	-17.27M	-14.61M	-20.52M	-27.69M	-31.38M	-27.62M
Net Interest Income+	0	0	0	0	0	0	6K	877K	4.34M	4.05M
Interest Income	0	0	0	0	0	0	6K	877K	4.34M	4.05M
Interest Expense	0	0	192.82K	0	0	0	0	0	0	0
Other Income/Expense	431	0	-473.41K	29.3K	25.65K	-3.22M	-85K	731K	1.28M	2.12M
Pretax Income+	-12.76M	-6.37M	-8.12M	-11.4M	-17.24M	-17.83M	-20.61M	-26.96M	-30.09M	-25.5M
Pretax Margin %	-7257.22%	-	-	-	-	-	-	-	-	-
Income Tax+	0	-1.76M	0	-29.3K	0	0	0	0	0	0
Effective Tax Rate %	1.24%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-15.76M	-6.37M	-8.12M	-11.4M	-17.24M	-17.83M	-20.61M	-26.96M	-30.09M	-25.5M
Net Margin %	-8964.92%	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.08%	0.6%	-0.28%	-0.4%	-0.51%	-0.03%	-0.16%	-0.31%	-0.12%	0.15%
Net Income (Continuing)	-12.76M	-6.37M	-8.12M	-11.4M	-17.24M	-17.83M	-20.61M	-26.96M	-30.09M	-25.5M
Discontinued Operations	-2.33M	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-99.79	-25.93	-8.33	-2.74	-2.03	-1.97	-0.18	-0.21	-0.24	-0.20
EPS Growth %	0.09%	0.74%	0.68%	0.67%	0.26%	0.03%	0.91%	-0.17%	-0.14%	0.17%
EPS (Basic)	-99.79	-25.93	-8.33	-2.74	-2.03	-1.97	-0.18	-0.21	-0.24	-0.20
Diluted Shares Outstanding	157.93K	245.6K	974.77K	4.16M	8.5M	11.31M	116.95M	126.62M	126.08M	125.86M
Basic Shares Outstanding	157.93K	245.6K	974.77K	4.16M	8.5M	11.31M	116.95M	126.62M	126.08M	125.86M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.29M	3.25M	7.9M	11.55M	14.32M	42.77M	141.24M	118.2M	92.22M	74.46M
Cash & Short-Term Investments	3.72M	3.03M	7.22M	10.38M	12.69M	39.66M	136.38M	110.89M	88.46M	71.08M
Cash Only	3.72M	3.03M	7.22M	10.38M	12.69M	39.66M	136.38M	110.89M	88.46M	71.08M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	358.28K	518.1K	739.66K	634.94K	1.07M	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	305.94K	619.83K	0	0	0	5.25M	1.49M	0
Days Inventory Outstanding	-	-	865.7	5.12K	-	-	-	-	-	-
Other Current Assets	385.66K	55K	71.34K	140.94K	40.35K	671.88K	1.3M	853K	977K	229K
Total Non-Current Assets+	1.95M	889.81K	266.06K	171.08K	181.37K	73.07K	22K	5.33M	4.03M	1.99M
Property, Plant & Equipment	171.57K	55.12K	11.47K	54.49K	84.83K	38.69K	20K	0	0	0
Fixed Asset Turnover	0.01x	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.7M	640.44K	75.69K	99.38K	68.54K	13.38K	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	4.7M	1.71M	0
Other Non-Current Assets	76.34K	194.25K	178.91K	17.22K	17.22K	17.22K	2K	635K	2.32M	1.99M
Total Assets+	6.24M	4.14M	8.16M	11.72M	14.5M	42.84M	141.26M	123.53M	96.25M	76.44M
Asset Turnover	0.00x	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.47%	-0.34%	0.97%	0.44%	0.24%	1.95%	2.3%	-0.13%	-0.22%	-0.21%
Total Current Liabilities+	2.5M	1.05M	1.23M	2.92M	1.32M	15.67M	3.13M	5.57M	5.24M	4.97M
Accounts Payable	814.45K	254.32K	334.9K	353.33K	293.17K	1.59M	1.72M	2.96M	806K	679K
Days Payables Outstanding	2.25K	305.87	947.63	2.92K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	39.37K	18.05K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	621.62K	89.09K	105.64K	217.01K	90.78K	13.1M	1.1M	19K	1.8M	3.04M
Current Ratio	1.72x	3.11x	6.45x	3.96x	10.83x	2.73x	45.18x	21.23x	17.61x	14.99x
Quick Ratio	1.72x	3.11x	6.20x	3.75x	10.83x	2.73x	45.18x	20.29x	17.33x	14.99x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	814.45K	254.32K	334.9K	353.33K	21.89K	3.79K	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	11.11K	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	10.78K	3.79K	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	2.5M	1.05M	1.23M	2.92M	1.34M	15.68M	3.13M	5.57M	5.24M	4.97M
Total Debt+	0	0	0	0	50.48K	18.05K	0	0	0	0
Net Debt	-3.72M	-3.03M	-7.22M	-10.38M	-12.64M	-39.65M	-136.38M	-110.89M	-88.46M	-71.08M
Debt / Equity	-	-	-	-	0.00x	0.00x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-39.67x	-	-	-	-	-	-	-
Total Equity+	3.74M	3.1M	6.94M	8.81M	13.16M	27.17M	138.14M	117.96M	91.02M	71.48M
Equity Growth %	-0.61%	-0.17%	1.24%	0.27%	0.49%	1.07%	4.08%	-0.15%	-0.23%	-0.21%
Book Value per Share	23.69	12.61	7.12	2.12	1.55	2.40	1.18	0.93	0.72	0.57
Total Shareholders' Equity	3.74M	3.1M	6.94M	8.81M	13.16M	27.17M	138.14M	117.96M	91.02M	71.48M
Common Stock	32.66K	56.8K	477.34K	1.05M	1.64M	8.56M	22.79M	22.79M	22.79M	23.49M
Retained Earnings	-50.93M	-57.3M	-65.43M	-76.83M	-94.07M	-111.9M	-129.23M	-156.19M	-186.29M	-211.79M
Treasury Stock	0	0	0	0	0	0	0	0	-1.48M	-1.48M
Accumulated OCI	-114.29K	-155.41K	-159.45K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.95M	-5.37M	-6.59M	-8.96M	-9.13M	-11.57M	-16.47M	-20.76M	-20.94M	-21.03M
Operating CF Margin %	-7937.03%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.32%	0.61%	-0.23%	-0.36%	-0.02%	-0.27%	-0.42%	-0.26%	-0.01%	-0%
Net Income	-12.76M	-6.37M	-8.12M	-11.4M	-17.24M	-17.83M	-20.61M	-26.96M	-30.09M	-25.5M
Depreciation & Amortization	272.63K	303.48K	128.99K	44.2K	52.79K	46.52K	23K	8K	23K	17K
Stock-Based Compensation	840.1K	876.19K	786.55K	2.46M	0	3.02M	5.27M	6.79M	4.62M	2.29M
Deferred Taxes	-3.47M	-712.86K	760.16K	0	0	2.36M	0	0	0	0
Other Non-Cash Items	840.1K	1.6M	192.82K	2.69M	8.85M	939.2K	0	3K	2.99M	1.72M
Working Capital Changes	326.1K	-1.07M	-339.89K	-64.41K	-791.3K	-111.35K	-1.16M	-599K	1.52M	448K
Change in Receivables	321.05K	0	-358.28K	-159.82K	-221.56K	104.72K	-437K	329K	743K	0
Change in Inventory	9.28K	0	0	0	0	-104.72K	437K	-329K	0	-611K
Change in Payables	301.4K	-560.13K	80.58K	18.43K	-60.16K	1.3M	128K	1.25M	-2.16M	-127K
Cash from Investing+	-288.42K	-9.21K	0	-110.91K	-7.63K	-9.37K	-9K	-4.73M	-14K	-19K
Capital Expenditures	-130.74K	-9.21K	0	-110.91K	-7.63K	-9.37K	-9K	-27K	-14K	-19K
CapEx % of Revenue	74.37%	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-157.68K	-9.21K	0	-110.91K	0	0	0	0	0	0
Cash from Financing+	9.46M	4.7M	10.78M	12.29M	11.34M	38.55M	113.3M	0	-1.48M	3.67M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	749.23K	0	0	-13.82K	43.64M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-14.08M	-5.38M	-6.59M	-9.07M	-9.14M	-11.58M	-16.48M	-20.79M	-20.95M	-21.05M
FCF Margin %	-8011.39%	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.29%	0.62%	-0.22%	-0.38%	-0.01%	-0.27%	-0.42%	-0.26%	-0.01%	-0%
FCF per Share	-89.18	-21.92	-6.76	-2.18	-1.08	-1.02	-0.14	-0.16	-0.17	-0.17
FCF Conversion (FCF/Net Income)	0.89x	0.84x	0.81x	0.79x	0.53x	0.65x	0.80x	0.77x	0.70x	0.82x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-238.07%	-186.26%	-161.87%	-144.88%	-157%	-88.42%	-24.93%	-21.05%	-28.8%	-31.39%
Return on Invested Capital (ROIC)	-1666.36%	-12584.24%	-	-	-	-	-	-470.24%	-488.74%	-1404.93%
Gross Margin	-7431.91%	-	-	-	-	-	-	-	-	-
Net Margin	-896491.64%	-	-	-	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.00x	0.00x	-	-	-	-
Interest Coverage	-	-	-39.67x	-	-	-	-	-	-	-
FCF Conversion	0.89x	0.84x	0.81x	0.79x	0.53x	0.65x	0.80x	0.77x	0.70x	0.82x
Revenue Growth	-99.67%	-100%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Atossa Therapeutics, Inc. (ATOS) grew revenue by 0.0% over the past year. Growth has been modest.

Atossa Therapeutics, Inc. (ATOS) reported a net loss of $30.2M for fiscal year 2024.

Dividend & Returns

Atossa Therapeutics, Inc. (ATOS) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.

Atossa Therapeutics, Inc. (ATOS) had negative free cash flow of $26.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Atossa Therapeutics, Inc. (ATOS) 10-Year Financial Performance & Capital Metrics

ATOS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$28M +12.0%
Net Income -$26M +15.3%
EPS (Diluted) -0.20 +16.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -31.39% -9.0%
ROIC -1404.93% -187.5%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-12.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM-10.68%

ROCE

10Y Avg-106.27%

5Y Avg-36.58%

3Y Avg-28.55%

Latest-34%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.76K	0	0	0	0	0	0	0	0	0
Revenue Growth %	-1%	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	132.41K	303.48K	128.99K	44.2K	0	0	0	0	0	0
COGS % of Revenue	75.32%	-	-	-	-	-	-	-	-	-
Gross Profit+	-130.65K	-303.48K	-128.99K	-44.2K	0	0	0	0	0	0
Gross Margin %	-74.32%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-1.71%	-1.32%	0.57%	0.66%	1%	-	-	-	-	-
Operating Expenses+	12.63M	7.25M	7.19M	11.43M	17.27M	14.61M	20.52M	27.69M	31.38M	27.62M
OpEx % of Revenue	7183.14%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	10.27M	6.48M	4.86M	7.22M	10.62M	8M	11.31M	12.61M	14.04M	13.5M
SG&A % of Revenue	5840.94%	-	-	-	-	-	-	-	-	-
Research & Development	2.36M	770.43K	2.33M	4.21M	7.13M	6.61M	9.21M	15.08M	17.33M	14.12M
R&D % of Revenue	1342.2%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	718.97K	154	29.3K	-486.55K	0	0	0	0	0
Operating Income+	-12.76M	-7.97M	-7.65M	-11.43M	-17.27M	-14.61M	-20.52M	-27.69M	-31.38M	-27.62M
Operating Margin %	-7257.46%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.13%	0.38%	0.04%	-0.49%	-0.51%	0.15%	-0.4%	-0.35%	-0.13%	0.12%
EBITDA+	-12.49M	-7.67M	-7.52M	-11.39M	-17.21M	-14.56M	-20.5M	-27.68M	-31.35M	-27.6M
EBITDA Margin %	-7102.38%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.11%	0.39%	0.02%	-0.51%	-0.51%	0.15%	-0.41%	-0.35%	-0.13%	0.12%
D&A (Non-Cash Add-back)	272.63K	303.48K	128.99K	44.2K	52.79K	47K	23K	8K	23K	17K
EBIT	-12.76M	-6.37M	-7.93M	-11.43M	-17.27M	-14.61M	-20.52M	-27.69M	-31.38M	-27.62M
Net Interest Income+	0	0	0	0	0	0	6K	877K	4.34M	4.05M
Interest Income	0	0	0	0	0	0	6K	877K	4.34M	4.05M
Interest Expense	0	0	192.82K	0	0	0	0	0	0	0
Other Income/Expense	431	0	-473.41K	29.3K	25.65K	-3.22M	-85K	731K	1.28M	2.12M
Pretax Income+	-12.76M	-6.37M	-8.12M	-11.4M	-17.24M	-17.83M	-20.61M	-26.96M	-30.09M	-25.5M
Pretax Margin %	-7257.22%	-	-	-	-	-	-	-	-	-
Income Tax+	0	-1.76M	0	-29.3K	0	0	0	0	0	0
Effective Tax Rate %	1.24%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-15.76M	-6.37M	-8.12M	-11.4M	-17.24M	-17.83M	-20.61M	-26.96M	-30.09M	-25.5M
Net Margin %	-8964.92%	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.08%	0.6%	-0.28%	-0.4%	-0.51%	-0.03%	-0.16%	-0.31%	-0.12%	0.15%
Net Income (Continuing)	-12.76M	-6.37M	-8.12M	-11.4M	-17.24M	-17.83M	-20.61M	-26.96M	-30.09M	-25.5M
Discontinued Operations	-2.33M	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-99.79	-25.93	-8.33	-2.74	-2.03	-1.97	-0.18	-0.21	-0.24	-0.20
EPS Growth %	0.09%	0.74%	0.68%	0.67%	0.26%	0.03%	0.91%	-0.17%	-0.14%	0.17%
EPS (Basic)	-99.79	-25.93	-8.33	-2.74	-2.03	-1.97	-0.18	-0.21	-0.24	-0.20
Diluted Shares Outstanding	157.93K	245.6K	974.77K	4.16M	8.5M	11.31M	116.95M	126.62M	126.08M	125.86M
Basic Shares Outstanding	157.93K	245.6K	974.77K	4.16M	8.5M	11.31M	116.95M	126.62M	126.08M	125.86M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.29M	3.25M	7.9M	11.55M	14.32M	42.77M	141.24M	118.2M	92.22M	74.46M
Cash & Short-Term Investments	3.72M	3.03M	7.22M	10.38M	12.69M	39.66M	136.38M	110.89M	88.46M	71.08M
Cash Only	3.72M	3.03M	7.22M	10.38M	12.69M	39.66M	136.38M	110.89M	88.46M	71.08M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	358.28K	518.1K	739.66K	634.94K	1.07M	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	305.94K	619.83K	0	0	0	5.25M	1.49M	0
Days Inventory Outstanding	-	-	865.7	5.12K	-	-	-	-	-	-
Other Current Assets	385.66K	55K	71.34K	140.94K	40.35K	671.88K	1.3M	853K	977K	229K
Total Non-Current Assets+	1.95M	889.81K	266.06K	171.08K	181.37K	73.07K	22K	5.33M	4.03M	1.99M
Property, Plant & Equipment	171.57K	55.12K	11.47K	54.49K	84.83K	38.69K	20K	0	0	0
Fixed Asset Turnover	0.01x	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.7M	640.44K	75.69K	99.38K	68.54K	13.38K	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	4.7M	1.71M	0
Other Non-Current Assets	76.34K	194.25K	178.91K	17.22K	17.22K	17.22K	2K	635K	2.32M	1.99M
Total Assets+	6.24M	4.14M	8.16M	11.72M	14.5M	42.84M	141.26M	123.53M	96.25M	76.44M
Asset Turnover	0.00x	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.47%	-0.34%	0.97%	0.44%	0.24%	1.95%	2.3%	-0.13%	-0.22%	-0.21%
Total Current Liabilities+	2.5M	1.05M	1.23M	2.92M	1.32M	15.67M	3.13M	5.57M	5.24M	4.97M
Accounts Payable	814.45K	254.32K	334.9K	353.33K	293.17K	1.59M	1.72M	2.96M	806K	679K
Days Payables Outstanding	2.25K	305.87	947.63	2.92K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	39.37K	18.05K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	621.62K	89.09K	105.64K	217.01K	90.78K	13.1M	1.1M	19K	1.8M	3.04M
Current Ratio	1.72x	3.11x	6.45x	3.96x	10.83x	2.73x	45.18x	21.23x	17.61x	14.99x
Quick Ratio	1.72x	3.11x	6.20x	3.75x	10.83x	2.73x	45.18x	20.29x	17.33x	14.99x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	814.45K	254.32K	334.9K	353.33K	21.89K	3.79K	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	11.11K	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	10.78K	3.79K	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	2.5M	1.05M	1.23M	2.92M	1.34M	15.68M	3.13M	5.57M	5.24M	4.97M
Total Debt+	0	0	0	0	50.48K	18.05K	0	0	0	0
Net Debt	-3.72M	-3.03M	-7.22M	-10.38M	-12.64M	-39.65M	-136.38M	-110.89M	-88.46M	-71.08M
Debt / Equity	-	-	-	-	0.00x	0.00x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-39.67x	-	-	-	-	-	-	-
Total Equity+	3.74M	3.1M	6.94M	8.81M	13.16M	27.17M	138.14M	117.96M	91.02M	71.48M
Equity Growth %	-0.61%	-0.17%	1.24%	0.27%	0.49%	1.07%	4.08%	-0.15%	-0.23%	-0.21%
Book Value per Share	23.69	12.61	7.12	2.12	1.55	2.40	1.18	0.93	0.72	0.57
Total Shareholders' Equity	3.74M	3.1M	6.94M	8.81M	13.16M	27.17M	138.14M	117.96M	91.02M	71.48M
Common Stock	32.66K	56.8K	477.34K	1.05M	1.64M	8.56M	22.79M	22.79M	22.79M	23.49M
Retained Earnings	-50.93M	-57.3M	-65.43M	-76.83M	-94.07M	-111.9M	-129.23M	-156.19M	-186.29M	-211.79M
Treasury Stock	0	0	0	0	0	0	0	0	-1.48M	-1.48M
Accumulated OCI	-114.29K	-155.41K	-159.45K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.95M	-5.37M	-6.59M	-8.96M	-9.13M	-11.57M	-16.47M	-20.76M	-20.94M	-21.03M
Operating CF Margin %	-7937.03%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.32%	0.61%	-0.23%	-0.36%	-0.02%	-0.27%	-0.42%	-0.26%	-0.01%	-0%
Net Income	-12.76M	-6.37M	-8.12M	-11.4M	-17.24M	-17.83M	-20.61M	-26.96M	-30.09M	-25.5M
Depreciation & Amortization	272.63K	303.48K	128.99K	44.2K	52.79K	46.52K	23K	8K	23K	17K
Stock-Based Compensation	840.1K	876.19K	786.55K	2.46M	0	3.02M	5.27M	6.79M	4.62M	2.29M
Deferred Taxes	-3.47M	-712.86K	760.16K	0	0	2.36M	0	0	0	0
Other Non-Cash Items	840.1K	1.6M	192.82K	2.69M	8.85M	939.2K	0	3K	2.99M	1.72M
Working Capital Changes	326.1K	-1.07M	-339.89K	-64.41K	-791.3K	-111.35K	-1.16M	-599K	1.52M	448K
Change in Receivables	321.05K	0	-358.28K	-159.82K	-221.56K	104.72K	-437K	329K	743K	0
Change in Inventory	9.28K	0	0	0	0	-104.72K	437K	-329K	0	-611K
Change in Payables	301.4K	-560.13K	80.58K	18.43K	-60.16K	1.3M	128K	1.25M	-2.16M	-127K
Cash from Investing+	-288.42K	-9.21K	0	-110.91K	-7.63K	-9.37K	-9K	-4.73M	-14K	-19K
Capital Expenditures	-130.74K	-9.21K	0	-110.91K	-7.63K	-9.37K	-9K	-27K	-14K	-19K
CapEx % of Revenue	74.37%	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-157.68K	-9.21K	0	-110.91K	0	0	0	0	0	0
Cash from Financing+	9.46M	4.7M	10.78M	12.29M	11.34M	38.55M	113.3M	0	-1.48M	3.67M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	749.23K	0	0	-13.82K	43.64M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-14.08M	-5.38M	-6.59M	-9.07M	-9.14M	-11.58M	-16.48M	-20.79M	-20.95M	-21.05M
FCF Margin %	-8011.39%	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.29%	0.62%	-0.22%	-0.38%	-0.01%	-0.27%	-0.42%	-0.26%	-0.01%	-0%
FCF per Share	-89.18	-21.92	-6.76	-2.18	-1.08	-1.02	-0.14	-0.16	-0.17	-0.17
FCF Conversion (FCF/Net Income)	0.89x	0.84x	0.81x	0.79x	0.53x	0.65x	0.80x	0.77x	0.70x	0.82x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-238.07%	-186.26%	-161.87%	-144.88%	-157%	-88.42%	-24.93%	-21.05%	-28.8%	-31.39%
Return on Invested Capital (ROIC)	-1666.36%	-12584.24%	-	-	-	-	-	-470.24%	-488.74%	-1404.93%
Gross Margin	-7431.91%	-	-	-	-	-	-	-	-	-
Net Margin	-896491.64%	-	-	-	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.00x	0.00x	-	-	-	-
Interest Coverage	-	-	-39.67x	-	-	-	-	-	-	-
FCF Conversion	0.89x	0.84x	0.81x	0.79x	0.53x	0.65x	0.80x	0.77x	0.70x	0.82x
Revenue Growth	-99.67%	-100%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Atossa Therapeutics, Inc. (ATOS) grew revenue by 0.0% over the past year. Growth has been modest.

Atossa Therapeutics, Inc. (ATOS) reported a net loss of $30.2M for fiscal year 2024.

Dividend & Returns

Atossa Therapeutics, Inc. (ATOS) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.

Atossa Therapeutics, Inc. (ATOS) had negative free cash flow of $26.3M in fiscal year 2024, likely due to heavy capital investments.